Table 6 Clinical trials evaluating antibody–drug conjugates and analogues in patients with TNBC
From: Recent advances in therapeutic strategies for triple-negative breast cancer
Drugs | Category | Target | Payload | Register ID | Phase | Status |
|---|---|---|---|---|---|---|
Sacituzumab govitecan | ADC | Trop-2 | SN-38 | NCT04468061 | II | Recruiting |
NCT04454437 | IIb | Active | ||||
NCT04230109 | II | Active | ||||
NCT04595565 | III | Recruiting | ||||
Datopotamab deruxtecan | ADC | Trop-2 | Deruxtecan | NCT03401385 | I | Recruiting |
SKB264 | ADC | Trop-2 | Belotecan-derived payload | NCT04152499 | I-II | Recruiting |
Mirvetuximab soravtansine | ADC | Folate receptor α | DM4 | NCT02996825 | I | Active |
NCT03106077 | II | Completed* | ||||
Ladiratuzumab vedotin | ADC | Zinc transporter LIV-1 | MMAE | NCT03310957 | Ib/II | Recruiting |
NBE-002 | ADC | ROR1 | Anthracycline | NCT04441099 | I/II | Recruiting |
VLS-101 | ADC | ROR1 | MMAE | NCT04504916 | II | Recruiting |
BA3021 | PDC | ROR2 | Unpublished | NCT03504488 | I/II | Recruiting |
Camidanlumab tesirine | ADC | CD25 | Pyrrolobenzodiazepine | NCT03621982 | Ib | Recruiting |
Praluzatamab ravtansine | PDC | CD166 | DM4 | NCT04596150 | II | Recruiting |
MGC018 | ADC | CD276 | Duocarmycin | NCT03729596 | I/II | Recruiting |
Anti-EGFR-IL-dox | Immunoliposomes | EGFR | Doxorubicin | NCT02833766 | II | Unpublished |
Trastuzumab deruxtecan | ADC | HER2 | Deruxtecan | NCT04556773 | Ib | Recruiting |
Patritumab deruxtecan | ADC | HER3 | Deruxtecan | NCT04699630 | II | Recruiting |
Anetumab ravtansine | ADC | Mesothelin | DM4 | NCT03102320 | Ib | Unpublished |
NCT02485119 | I | Unpublished | ||||
Cofetuzumab pelidotin | ADC | Protein tyrosine kinase 7 | Aur0101 | NCT03243331 | I | Unpublished |
Enfortumab vedotin | ADC | Nectin-4 | MMAE | NCT04225117 | II | Recruiting |
BT8009 | Peptide drug conjugate | Nectin-4 | MMAE | NCT04561362 | I/II | Recruiting |
TH1902 peptide | Peptide drug conjugate | Sortilin | Docetaxel | NCT04706962 | I | Recruiting |